Exvade Bioscience™, a clinical-stage neuro-oncology company advancing a breakthrough platform for treating aggressive brain cancers, today highlighted ongoing enrollment in a Phase 1 clinical trial ...

A nano-sized medicine boosts the anti-cancer immune response and eradicates tumors in mice. Researchers at Washington University School of Medicine in St. Louis, working with colleagues at ...

UW researchers found potential new treatments for a rare pediatric brain cancer each year that has a median survival time of ...

A Chanhassen-based medical company has raised $52 million in its quest to treat an aggressive form of brain cancer. Late last week, Alpheus Medical Inc. announced that it closed its Series B funding ...

Researchers at the UNC School of Medicine and the UNC Eshelman School of Pharmacy have made a breakthrough that could ...

As brain tumors grow, they must do one of two things: push against the brain or use finger-like extensions to invade and destroy surrounding tissue. Previous research found tumors that push - or put ...

Victorian brain cancer researchers have achieved a global-first, using an innovative process to learn how a new drug suppresses tumor activity and provides hope to patients with low-grade gliomas (LGG ...

University of Kentucky Markey Cancer Center researchers have discovered a genetic biomarker that could help identify patients with glioblastoma most likely to benefit from the cancer drug bevacizumab.

As long-term cancer survival outcomes improve, the brain has increasingly become a site of refractory and recurrent disease. At Memorial Sloan Kettering Cancer Center (MSK), neurosurgeon Nelson Moss, ...